Tag: concept

VALENCIA, Spain, June 12, 2025 (GLOBE NEWSWIRE) -- Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of leading-edge, AI-optimized solar energy storage technologies and solutions, today announced that it has been granted a new patent for its innovative system designed to integrate energy storage and expand photovoltaic generation in upstream installations. The patented system provides a unique method for enhancing energy efficiency and flexibility in self-consumption solar power systems—particularly those configured to prevent surplus energy from being injected into the electrical grid.

SkiStar AB will publish the Interim Report for the period 1 September 2024 – 31 May 2025 on Thursday 19 June 2025 at 07.00 a.m. CEST. In connection with the report SkiStar will organize a conference call with web presentation. CEO Stefan Sjöstrand and CFO Sara J Uggelberg will present and comment on the report. After the presentation there will be time for questions, both by phone and by chat in the web presentation. The presentation will be held in English.

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

AKVA group ASA (“AKVA”) today hosts a Capital Markets Day where it introduces a revenue target of NOK 5 billion and an EBIT target of 9% for 2027 and outlines its ambitions for continued profitable growth to NOK 7 billion in 2030.

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.